中国普通外科杂志2019，Vol.34Issue(8)：696-699,4.DOI:10.3670.cma.j.issn.1007-631X.2019.08.014
特利加压素治疗肝硬化合并肝癌术后腹腔积液的临床疗效观察
Teripressin for the treatment of postoperative ascites in cirrhotic liver cancer patients
摘要
Abstract
Objective To analyze the clinical efficacy of teripressin in the treatment of postoperative ascites in patients with cirrhosis and liver cancer.Method 90 patients were divided into experimental group treated with terlipressin on the basis of routine and diuretic treatment,and control group treated with routine and diuretics only.Result There was significant difference in urine volume between the two groups (F =39 401.325,P =0.000).The amount of urine in the experimental group was more than that in the control group.The amount of peritoneal effusion significantly increased after operation (F=265.163,P =0.000),and that in the experimental group was more than that in the control group (F =6.470,P =0.044).The levels of serum creatinine,urea nitrogen,sodium and blood in the two groups were higher than those in the control group (F =6.470,P =0.044).The change of potassium was not obvious,and the difference was not statistically significant (P＞ 0.05).The average hospitalization time in the experimental group and the control group were (22.2 ± 3.1) d,(26.6 ± 5.1) d respectively,(t=-4.945,P =0.001).Conclusion Terlipressin is effective and safe in the treatment of peritoneal effusion after hepatic cirrhosis combined with hepatocellular carcinoma.关键词
癌,肝细胞/肝硬化/高血压,门静脉Key words
Carcinoma, hepatocellular/Liver Cirrhosis/Hypertension, portal引用本文复制引用
蔡建平,周湘鸿,余海波,王连才,李德宇..特利加压素治疗肝硬化合并肝癌术后腹腔积液的临床疗效观察[J].中国普通外科杂志,2019,34(8):696-699,4.基金项目
河南省科技厅重点科技攻关项目(132102310096) （132102310096）
河南省卫生厅医学科技攻关项目(201403177)Key Science and Technology Research Projects of Henan Science and Technology Department (132102310096) （201403177）
Medical Science and Technology Tackling Project of Henan Provincial Department of Health(201403177) （201403177）
